SEC Company Response from GSK (GSK) — Sep 26, 2006
GSK plc
Date: Sept. 26, 2006 · CIK: 0001131399 · Accession: 0000903423-06-001071
AI Filing Summary & Sentiment
Referenced dates: September 19, 2006
Letter
Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 United States Re: Comment Letter—GlaxoSmithKline PLC (“GSK”) Annual Report on Form 20-F for 2005
Dear Mr. Rosenberg:
We appreciate the opportunity to speak with your colleague Sasha Parikh yesterday in connection with the comment letter dated September 19, 2006 relating to GSK’s Annual Report for 2005. As requested, this is a brief note to indicate that GSK intends to respond to the comments by October 31, 2006.
Although the comments are not extensive, the preparation of appropriate responses will require the involvement of a number of GSK executives and financial and legal department staff, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult, particularly given the fact that GSK will shortly be in the midst of preparing its third quarter results.
Mr. Jim B. Rosenberg, p. 2
You can reach either me, or my colleague Adam Schneider, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Ms. Sasha Parikh, Securities and Exchange Commission
Ms. Lisa Vanjoske, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline PLC
Mr. Simon Friend, PricewaterhouseCoopers
Mr. Adam Schneider, Cleary Gottlieb Steen & Hamilton LLP
Show Raw Text
CORRESP
1
filename1.htm
E-Mail: ssperber@cgsh.com
September 26, 2006
BY EDGAR
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Division of Corporation Finance
Securities and Exchange Commission
Washington, D.C. 20549
United States
Re: Comment Letter—GlaxoSmithKline PLC (“GSK”) Annual Report on Form 20-F for 2005
Dear Mr. Rosenberg:
We appreciate the opportunity to speak with your colleague Sasha Parikh yesterday in connection with the comment letter dated September 19, 2006 relating to GSK’s Annual Report for 2005. As requested, this is a brief note to indicate that GSK intends to respond to the comments by October 31, 2006.
Although the comments are not extensive, the preparation of appropriate responses will require the involvement of a number of GSK executives and financial and legal department staff, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult, particularly given the fact that GSK will shortly be in the midst of preparing its third quarter results.
Mr. Jim B. Rosenberg, p. 2
You can reach either me, or my colleague Adam Schneider, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Ms. Sasha Parikh, Securities and Exchange Commission
Ms. Lisa Vanjoske, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline PLC
Mr. Simon Friend, PricewaterhouseCoopers
Mr. Adam Schneider, Cleary Gottlieb Steen & Hamilton LLP